Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
This research study is for liver transplant recipients and their respective living donors.
The purpose of this study is:
1. To see if it is safe for liver recipients to receive one dose of donor reactive T
regulatory cells (Tregs)
2. To see if the Tregs allows a liver recipient to take less, or completely stop
medications normally taken after receiving an organ transplant.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Clinical Trials in Organ Transplantation in Children Rho Federal Systems Division, Inc.